×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Liver Cancer

Debu Tripathy, M.D.
In the spring 2020 issue of CURE®, Editor-in-Chief Dr. Debu Tripathy details how preventing liver cancer starts with understanding the precursors to cancer’s development.
 
Heather Stringer
Nonalcoholic fatty liver disease can lead to cancer. Patients can reverse the damage through diet and exercise, but how can they know if they have the common condition?
 
Ryan McDonald
The Food and Drug Administration’s recent approval of Pemazyre (pemigatinib) is a ‘huge milestone’ for patients with cholangiocarcinoma, according to the advocacy coordinator with the Cholangiocarcinoma Foundation.
 
Jessica Skarzynski
Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for April 2020.
 
SPONSORED CONTENT
A gastrointestinal malignancy expert discusses the role genomics play in cholangiocarcinoma, as well as how genetic profiling may identify which treatment is best for patients.
 
Kristie L. Kahl
The Food and Drug Administration approved Pemazyre for the treatment of patients with previously treated, advanced cholangiocarcinoma.
Ryan McDonald
Although the new coronavirus has led to a delay in some cholangiocarcinoma trials, experts don’t expect the trials to come to an end.
 
Conor Killmurray
The Food and Drug Administration approved the dual immunotherapy of Opdivo and Yervoy for the treatment of patients with advanced hepatocellular carcinoma. Here’s what you need to know.
 
Conor Killmurray
The Food and Drug Administration granted an accelerated approval to the combination of Opdivo and Yervoy for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with Nexavar.
Sponsored Content
Researchers hope the new PROOF trial will show that infigratinib, a targeted drug, will expand options in treating advanced cholangiocarcinoma. Patients are enrolling now.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×